Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 06  •  04:00PM ET
1.49
Dollar change
-0.01
Percentage change
-0.67
%
Index- P/E- EPS (ttm)-0.47 Insider Own- Shs Outstand551.86M Perf Week4.93%
Market Cap822.27M Forward P/E- EPS next Y- Insider Trans- Shs Float22.85M Perf Month7.97%
Enterprise Value648.15M PEG- EPS next Q- Inst Own0.03% Short Float0.06% Perf Quarter-12.35%
Income-134.82M P/S55.67 EPS this Y- Inst Trans-16.43% Short Ratio0.97 Perf Half Y-14.37%
Sales14.77M P/B4.13 EPS next Y- ROA-68.04% Short Interest0.01M Perf YTD-9.15%
Book/sh0.36 P/C4.67 EPS next 5Y- ROE-79.90% 52W High2.10 -29.05% Perf Year21.14%
Cash/sh0.32 P/FCF806.15 EPS past 3/5Y17.69% 35.90% ROIC-67.69% 52W Low0.83 79.30% Perf 3Y254.76%
Dividend Est.- EV/EBITDA- Sales past 3/5Y35.00% 16.43% Gross Margin-1.90% Volatility12.20% 10.18% Perf 5Y-33.48%
Dividend TTM- EV/Sales43.88 EPS Y/Y TTM-145.92% Oper. Margin-26.54% ATR (14)0.15 Perf 10Y-
Dividend Ex-DateAug 01, 2018 Quick Ratio14.18 Sales Y/Y TTM510.69% Profit Margin-912.89% RSI (14)51.39 Recom-
Dividend Gr. 3/5Y- - Current Ratio14.20 EPS Q/Q40.33% SMA200.59% Beta-0.67 Target Price4.00
Payout- Debt/Eq0.01 Sales Q/Q25.47% SMA503.84% Rel Volume0.65 Prev Close1.50
Employees27 LT Debt/Eq0.00 Earnings- SMA200-4.63% Avg Volume15.04K Price1.49
IPONov 03, 2017 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume9,800 Change-0.67%
Akso Health Group operates a social e-commerce platform principally in China that collaborates with other domestic e-commerce platforms and offers users a wide selection of products. It also plans to develop a new business as a cancer therapy and radiotherapy oncology service provider with operations in the U.S. The firm plans to open 2 vaccine research centers and 100 radiation oncology centers to be located on the east coast serving cancer patients in need of varying stages of treatment, including specialized radiation therapy centers for radiotherapy, personalized consultation, conventional treatment planning, and other cancer related treatment services. The company was founded by Xiaobo An in March 2014 and is headquartered in Qingdao, China.